Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.

Jarem EdwardsAnnie TaskerInês Pires da SilvaCamelia QuekMarcel BattenAngela FergusonRuth AllenBenjamin AllansonRobyn P M SawJohn F ThompsonAlexander M MenziesUmaimainthan PalendiraJames S WilmottGeorgina V LongRichard A Scolyer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

This study provides the first comprehensive assessment of immune checkpoint receptor expression in any cancer and provides important data for rational selection of targets for trials and predictive biomarker development.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
papillary thyroid
risk factors
peritoneal dialysis
squamous cell carcinoma
cross sectional
randomized controlled trial
electronic health record
squamous cell
open label
lymph node metastasis
phase iii